Samsung Biologics expected to apply for Korea IPO approval on Aug 11 - exchange officials

SEOUL, Aug 8 (Reuters) - Samsung Biologics Co Ltd, the

biopharmaceutical contract manufacturing affiliate of Samsung

Group, is expected to apply on Thursday for Korea

Exchange approval for a planned initial public offering, two

exchange officials said on Monday.

Read more